ALT earnings / call / takeaways
ALT Q3 FY26 earnings call: key takeaways
What ALT said on its earnings call of November 12, 2026: results against expectations, what changed since last quarter, guidance and the questions analysts pressed on.
By Lician·November 12, 2026·AI-generated from the call transcript and Lician data
- ALT reported a net loss of $31.6 million, or $0.15 per share, for Q3 2026, which is in line with the consensus estimate of -$0.14 (21:45)
Results vs expectations
| Metric | Consensus | Reported | Result |
|---|---|---|---|
| EPS | -$0.14 | – | – |
EPS basis: Unverified: no SEC figure to check the provider EPS against
What changed since last quarter
- The company raised its guidance for the PERFORMA phase 3 trial, with a readout expected in 2029. (5:37)
- The company expects to have a clearer understanding of the AUD program's regulatory path after an end-of-phase-two meeting with the FDA in December. (14:03)
- The company is focusing on moderate to severe AUD patients, including those with advanced liver impairments, aligning with FDA guidance. (14:03)
What analysts pressed on
- Whether the AUD patient population with liver impairments will be included in the phase three trial. (43:41)
- How the company plans to address the commercial opportunity for Pemvidutide in the AUD market. (48:16)
- The potential impact of generic competition on pricing and commercial strategy for Pemvidutide. (50:36)
In their words
We believe Pemvidutide's differentiated profile positions it well across a multitude of patients.
Jerry (5:37)The strong results we saw significantly de-risked this program.
Jerry (5:37)We expect the top line data for RESTORE in the second half of 2027.
Christophe Arbet-Engels (15:27)Our conviction in Pemvidutide is stronger than ever.
Jerry (3:46)
Read the full transcript with the AI summary, or listen on the company's official webcast.
Every past call in full and transcript search come with Lician Pro.
Written by AI from the automatic transcript of the company's public webcast and Lician's earnings data. Each sentence cites the passage it comes from, and a sentence with a figure that is not in its sources was removed. Not investment advice.